Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

earch, organizational development and planning related to the return of full rights for quizartinib.

Other expenses (net) were $10.3 million and $3.6 million for the nine months ended September 30, 2013 and 2012, respectively.  The increase of $6.7 million was primarily due to the change in fair value of the Company's stock warrant liabilities, which is driven by the change in fair value of the underlying preferred or common securities.

At September 30, 2013, the Company had cash and equivalents of $78.9 million, compared to $17.5 million at December 31, 2012.  The increase of $61.4 million was primarily due to the completion of an initial public offering that raised net proceeds of $58.1 million and to the completion of a concurrent private offering that raised net proceeds of $25.1 million, less cash used to fund operations.

The Company expects its research and development expense to increase as it prepares for the initiation of the Phase 3 clinical trial of quizartinib in relapsed or refractory AML patients, which is expected to begin early in 2014.  Under the base case operating plan, which assumes that the FDA will require a randomized, controlled Phase 3 clinical trial for an NDA submission, the Company currently expects cash and cash equivalents to be sufficient to fund this trial and operations through the receipt of top line data from the Company's Phase 3 trial in approximately 326 relapsed/refractory AML patients. 

Conference Call and Webcast
A conference call hosted by the Ambit management team will be webcast live today at 2pm PT or 5pm ET and can be accessed by dialing 866-436-9172 for domestic callers and 630-691-2760 for international callers. Please specify that you would like to join the "Ambit Third Quarter 2013 Earnings Conference Call" and reference conference ID number 35424048.  If you are unable to listen to the live webcast, a teleconference replay will be available through Thursday,
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... OCTOBER 20-22, 2014: The 9th ... will take place at the Congress Center ... is now available at http://www.abim.ch . ... organizations from all over the globe will ... latest products and developments on the world ...
(Date:10/19/2014)... 19, 2014 The Asia-Pacific Speech Analytics ... in Asia-Pacific with analysis and forecast of revenue. This ... 2014 to $208 million by 2019, at a Compound ... 2019. , Browse through the TOC of the Asia-Pacific ... the in-depth analysis provided. It also provides a glimpse ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 According ... Products (Access Points; WLAN Controllers; Wireless gateways)]- Global ... and segments the global Outdoor Wi-Fi market with ... this report MarketsandMarkets also identifies the drivers and ... on the trends, opportunities and challenges. , Browse ...
(Date:10/18/2014)... The Asian arthroscopic devices report defines and ... forecast of revenue. The arthroscopic devices market in Asia ... at a CAGR of 6.5% from 2013 to 2018. ... devices market, to get an idea of the in-depth ... segmentation of arthroscopic devices market in the same region, ...
Breaking Biology Technology:The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 2Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 3Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 4The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 2The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 3The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 4
... April 4 /PRNewswire-FirstCall/ - ProMetic Life Sciences ... Rohwer, Pathogen,Removal and Diagnostics Technology Inc.,s ("PRDT") ... Research Scientist will present at,the American Chemical ... from April 6 - 10, 2008. Drs ...
... /Xinhua-PRNewswire-FirstCall/ -- WuXi,PharmaTech (Cayman) Inc. (NYSE: ... and medical device research and development,outsourcing company ... States, today,announced that it has filed a ... and Exchange Commission for a proposed follow-on ...
... FRANCISCO, Calif., and SINGAPORE, April 4, 2008 /PRNewswire/,-- ... on the,discovery and development of monoclonal antibody therapeutics ... today announced a,collaboration to advance the discovery of ... of the agreement, Raven will license its proprietary,whole ...
Cached Biology Technology:Prometic to present at the American Chemical Society 2Prometic to present at the American Chemical Society 3Prometic to present at the American Chemical Society 4WuXi PharmaTech (Cayman) Inc. Announces Filing of Registration Statement For Follow-On and Secondary Offering 2Raven biotechnologies and Bioprocessing Technology Institute Announce Collaboration to Advance Discovery of Stem Cell Antibodies 2
(Date:10/14/2014)... DURHAM, N.C. – Like discriminating thieves, prostate cancer tumors ... in the body. But such avarice may be a ... found a way to kill prostate cancer cells by ... that selectively destroys the diseased cells brimming with the ... which uses two drugs already commercially available for other ...
(Date:10/14/2014)... is how to produce enough food to feed the ... Agriculture Organization of the United Nations predicts that food ... to feed a growing global population, and plants are ... production. Plants—grains, cereals, fruits, vegetables, and more—feed humans ... must tap into our knowledge of how plants work ...
(Date:10/14/2014)... A team of scientists led by researchers at ... the University of Miami Miller School of Medicine ... genetic pathway underlying bipolar (manic depressive) disorder, a ... treating bipolar affective disorder, as well as depression ... findings, published online this week in Nature ...
Breaking Biology News(10 mins):Prostate cancer's penchant for copper may be a fatal flaw 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3Rare genetic disease protects against bipolar disorder 2Rare genetic disease protects against bipolar disorder 3
... the University Hospital and the Center for Applied Medical ... an article in Nature Cancer Reviews , one ... cancer studies. The article, written by Ignacio Melero and ... States and Great Britain, addresses the use of a ...
... This week's BMJ investigates a bitter row over a ... scrutiny once again. , The dispute has pitted a ... Cha, a fertility specialist and one of the most ... writes journalist Jonathan Gornall. It is also threatening to ...
... are obese don’t really know they are overweight, researchers have ... published by Cell Press. These findings in obese mice show ... critical fat hormone—causing a cascade of events that keeps energy ... metabolic pathway remains ready to respond. , “Obesity is not ...
Cached Biology News:Researchers from the University of Navarra analyze new kinds of cancer-fighting antibodies 2Row over study puts Korea's scientific community under scrutiny again 2In obesity, brain becomes 'unaware' of fat 2In obesity, brain becomes 'unaware' of fat 3
... system from Molecular Devices provides precise dispensing ... The system handles a variety of plate ... and 1536-welland is the first to handle ... optimized to dispense from four different channels ...
... ProteinPilot Software enables you to ... Now you can distinguish protein isoforms, ... You can also visualize peptide-protein associations ... ideal for protein identification and relative ...
... ( Abpromise for all tested ... Synthetic peptide: VEEESFGPQPISRLE conjugated to KLH, ... 15-29 of Human Rad51 ... Swiss Protein ID: ...
Rabbit polyclonal to Esa1 ( Abpromise for all tested applications)....
Biology Products: